Report: Glaxo pulling 170,000 H1N1 doses in Canada
Get the latest news alerts: Follow LTW at Twitter
Local Tech Wire
RESEARCH TRIANGLE PARK, N.C. — The CTV television network in Canada reported Friday that more than 100,000 doses of the H1N1 vaccine produced by GlaxoSmithKline (NYSE: GSK) are being withdrawn across the country because Manitoba health officials said they had noticed a higher-than-usual number of allergic reactions from one batch.
GlaxoSmithKline has asked several provinces to set aside the 170,000 doses from the questionable batch, the private TV network said.
GSK told the network that the recall is a precaution and they will investigate to see whether there is something wrong with the batch.
"GSK is taking this cautionary action because the Public Health Agency of Canada has received a higher than expected number of reports of anaphylaxis in this lot number compared to other lots," CTV quoted GSK as saying in a written statement Thursday.
One or two allergic reactions are expected in a batch that size, but health officials recorded six severe allergic reactions and alerted GSK.
Copyright 2012 WRAL Tech Wire. All rights reserved.
Featured
E-mail Preferences
The Skinny
- Will RTP-based ChannelAdvisor go public? They're thinking
- What brands are winning Super Bowl hype? Two Durham firms to find out
- In Super Bowl of social media, Patriots win, Triangle firm says
- Big job cuts coming at IBM? Don't be surprised
- Erskine Bowles is among those who can cash in big time on Facebook IPO
- Ignore Facebook hype - Check out 'risk factors,' too
- Facebook vs. Google IPO: Which deal ranks better?
- Triangle StartUp Factory says business already booming
- Entrepreneurship remains at heart of Tech Wire mission
- Flashback: Tech Wire launched 10 years ago today